Foa R - Search Results

1

Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings.

Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, Tos AG, Vischia F, Mandelli F, Gavosto F. Foa R, et al. Leukemia. 1992;6 Suppl 3:115S-116S. Leukemia. 1992. PMID: 1602806

2

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.

Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F. Meloni G, et al. Among authors: foa r. Blood. 1994 Oct 1;84(7):2158-63. Blood. 1994. PMID: 7919330 Free article. Clinical Trial.

3

Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients.

Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, Gillio Tos A, Mandelli F, Gavosto F. Foa R, et al. Recent Results Cancer Res. 1993;131:207-14. doi: 10.1007/978-3-642-84895-7_18. Recent Results Cancer Res. 1993. PMID: 8210640 No abstract available.

4

Interleukin 2 treatment in acute myelogenous leukemia.

Mandelli F, Vignetti M, Tosti S, Andrizzi C, Foa R, Meloni G. Mandelli F, et al. Among authors: foa r. Stem Cells. 1993 Jul;11(4):263-8. doi: 10.1002/stem.5530110402. Stem Cells. 1993. PMID: 8401249 Review.

5

Induction and Persistence of Complete Remission in a Resistant Acute Myeloid Leukemia Patient after Treatment with Recombinant Interleukin-2.

Foà R, Fierro MT, Tosti S, Meloni G, Gavosto F, Mandelli F. Foà R, et al. Leuk Lymphoma. 1990;1(2):113-7. doi: 10.3109/10428199009042467. Leuk Lymphoma. 1990. PMID: 27463816

6

Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.

Foa R, Guarini A, Gillio Tos A, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F. Foa R, et al. Cancer Res. 1991 Feb 1;51(3):964-8. Cancer Res. 1991. PMID: 1988139

7

Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study.

Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F. Foa R, et al. Br J Haematol. 1991 Apr;77(4):491-6. doi: 10.1111/j.1365-2141.1991.tb08615.x. Br J Haematol. 1991. PMID: 2025574

8

IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study.

Meloni G, Foà R, Tosti S, Vignetti M, Gavosto F, Mandelli F. Meloni G, et al. Among authors: foa r. Haematologica. 1990 Nov-Dec;75(6):502-5. Haematologica. 1990. PMID: 2098290

9

Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.

Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Guarini A, Cardona S, Gillio Tos A, Gavosto F, Mandelli F. Foa R, et al. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:98-102. Bone Marrow Transplant. 1990. PMID: 2202476 Clinical Trial. No abstract available.

10

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin.

Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarini A, Lista P, Pegoraro L, Mandelli F, Forni G, et al. Foa R, et al. Br J Haematol. 1990 May;75(1):34-40. doi: 10.1111/j.1365-2141.1990.tb02613.x. Br J Haematol. 1990. PMID: 2375921

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

937 results

Search Page

Filters